Volume 9, Issue 1 (Vol.9 No.1 Apr 2020)                   rbmb.net 2020, 9(1): 97-105 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mostafa-Hedeab G. ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review. rbmb.net. 2020; 9 (1) :97-105
URL: http://rbmb.net/article-1-503-en.html
Pharmacology department, Medical College, Jouf University, KSA. & Pharmacology department, Faculty of Medicine, Beni-Suef University, Egypt.
Abstract:   (109 Views)
Background: Since its first appearance in December of 2019, regular updates around the world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are increasing rapidly, indicating that not only does COVID-19 exhibit a rapid spread pattern, but human intervention is necessary for its resolution. Up until today (27-5-2020) and according to the World Health Organization (WHO), the number of confirmed COVID-19 cases has surpassed 4.5 million with more than 307, 500 deaths. Almost all countries have been affected by COVID-19, and resultingly, various drug trials have been conducted, however, a targeted treatment remains to be made accessible to the public. Recently, Angiotensin-Converting Enzyme-2 (ACE2) has gained some attention for its discovery as a potential attachment target of COVID-19.

Methods: We reviewed the most recent evidence regarding ACE2 distribution and action, the binding mechanism of COVID-19 and its correlation to cellular injury, ACE2 polymorphisms and its association to fatal COVID-19 and susceptibility and, finally, current ACE2-based pharmacotherapies against COVID-19.

Results: Blocking the ACE2 receptor-binding domain (RBD) using a specific ligand can prevent COVID-19 from binding, and consequently cellular entry and injury. Comparatively, soluble ACE2, which has a higher affinity to COVID-19, can neutralize COVID-19 without affecting the homeostatic function of naturally occurring ACE2. Lastly, ACE2 mutations and their possible effect on the binding activity of COVID-19 may enable researchers to identify high-risk groups before they become exposed to COVID-19.

Conclusions: ACE2 represents a promising target to attenuate or prevent COVID-19 associated cellular injury.
Keywords: ACE, ACE2, COVID-19.
Full-Text [PDF 211 kb]   (112 Downloads)    
Type of Article: Review | Subject: Molecular Biology
Received: 2020/05/21 | Accepted: 2020/06/8 | Published: 2020/07/18

Add your comments about this article : Your username or Email:

Send email to the article author

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb